Flow demonstrates effectiveness in both real-world data and clinical trials.
Flow has high response and remission rates - with no major side effects1-8.
In like-for-like open-label trials, the Flow tDCS Headset reports better remission and response rates compared to standard in-clinic tDCS3-4, antidepressants5-6, and talk therapy7.
The efficacy of tDCS for treating depression has been demonstrated across multiple studies between 2013-20203, 9-10. Together these trials reviewed the outcomes of 7,962 patients using in-clinic tDCS methods. Results across these studies showed tDCS is significantly superior to placebo9, and comparable to TMS10 and SSRI use3.
Flow internal data further demonstrates superiority in remission rates compared to other depression treatments8.
In order to access the stimulation headset, users are asked on a weekly basis to complete the Montgomery-Åsberg Depression Rating Scale self-assessment (MADRS-s).
This has enabled Flow to collect a significant amount of real-world data and continue to improve the product and services based on feedback.
Flow has been helpful for patients with mild, moderate, and severe depression types.
Flow has over 7,500+ headset users and covers patient cases from newly diagnosed to chronic8.
What our users say
“I hope after my lifetime Flow starts to replace meds. It has been rollercoaster of a life depending on horrible drugs with horrible side effects”
April 12, 2022
"I have been using flow for over 6 months and I’m definitely feeling more positive and this has had an upwards spiraling effect. Starting to eat better, exercise more etc which in turn makes you feel better."
May 02, 2022
"I’ve moved from a score of about 35 to 12 in the first month on their severity of depression chart. I would say it’s like I no longer feel suicidal or that there is a sense of impending doom"
June 22, 2021
1. Fu Cynthia H.Y., et al. J Psychiatr Res. 2022;153:197-205. 2. Borrione L, et al. J Affect Disord. 2021;288:189-190. 3. Brunoni AR, et al. JAMA Psychiatry. 2013;70(4):383-91. 4. Brunoni AR, et al. N Engl J Med. 2017; 376:2523-2533. 5. Machado M, et al. Current medical research and opinion. 2006;22(9),1825–1837. 6. Thase ME, et al. J Clin Psychiatry. 2005;66(8), 974–981. 7. Cuijpers P, et al. Acta Psychiatr Scand. 2021;144:288-299. 8. Data on File. 9. Razza LB, et al. Depress Anxiety. 2020;37:594-608. 10. Mutz J, et al. BMJ. 2019;364:l1079. 11. Trivedi et al. Am J Psychiatry. 2006;163(1):28-40. 12. O.E. Bogucki et al. J Affect Disord. 2021;294:745-752.